Takeda Pharmaceutical (TAK) Short-term Investments (2017 - 2026)

Takeda Pharmaceutical's Short-term Investments history runs 10 years deep, the most recent figure standing at $2.8 billion for Q1 2026.

• In Q1 2026, Short-term Investments rose 21.89% year-over-year to $2.8 billion; the TTM figure through Mar 2026 stood at $2.8 billion (up 21.89% YoY), while the FY2026 annual figure was $2.9 billion, up 26.79% from the prior year.
• Short-term Investments was $2.8 billion for Q1 2026 at Takeda Pharmaceutical, up from $2.8 billion in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $2.8 billion in Q1 2026 to a low of $101.8 million in Q1 2024.
• Historically, Short-term Investments has averaged $1.9 billion across 5 years, with a median of $2.2 billion in 2022.
• The sharpest annual moves came in 2022 and 2025: Short-term Investments tumbled 37.02% in 2022, then jumped 2160.39% in 2025.
• A 5-year view of Short-term Investments shows it stood at $1.9 billion in 2022, then decreased by 6.31% to $1.8 billion in 2023, then surged by 43.36% to $2.6 billion in 2024, then grew by 5.36% to $2.8 billion in 2025, then grew by 1.83% to $2.8 billion in 2026.
• The last three Short-term Investments figures came in at $2.8 billion (Q1 2026), $2.8 billion (Q4 2025), and $2.5 billion (Q3 2025), per Business Quant data.